According to filings with the U.S. Securities and Exchange Commission, Innova Vascular is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Innova Vascular
Innova Vascular is engaged in developing innovative medical devices for treating vascular disease using minimally invasive approach. Innova Vascular is located in beautiful southern California, which is a hub for medical device development for vascular disease. The area benefits from the availability of top engineering talent pool and leading academic institutions such as Cal Tech, UCLA, UCSD, UC Irvine, USC and others within a short drive.

To learn more about Innova Vascular, visit https://innovavascular.com/
Innova Vascular Linkedin Page: https://www.linkedin.com/company/innova-medical-inc/

Contact:
Sanjay Shrivastava, Chief Executive Officer
949-295-6040
https://www.linkedin.com/in/sanjay-shrivastava-ph-d-189260/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.